|
|
Post by oldfishtowner on Dec 7, 2020 11:42:02 GMT -5
But on a more serious note, and perhaps what Castagna had in mind for MNKD's COVID-19 activity:
"Fighting lung diseases including the novel Coronavirus by working to develop an inhaled form of Clofazimine. While this drug is intended to treat Tuberculosis and a related pathogen called Nontuberculous mycobacteria (NTM) we have recently found that it may be useful in the treatment of SARS-CoV-2 Coronavirus. We are currently conducting animal studies of this potential treatment through government and private funding.
We are also involved with another inhaled medication approach to treat Covid-19 and have made our knowledge of that treatment available to a partner company in Europe."
When the world wakes up and recognizes that the vaccines help, but are not a complete solution because the immunity has a finite lifetime and repeat doses may be required every 6-9 months (a logistical nightmare, especially when the vaccine must be kept in freezers) - medicines that provide treatment rather than prevention will be more valuable.
|
|
|
|
Post by mango on Dec 7, 2020 11:47:30 GMT -5
|
|
|
|
Post by goyocafe on Dec 7, 2020 11:49:18 GMT -5
“ We are currently conducting animal studies of this potential treatment through government and private funding.”
Would be curious how much government funding is in play here?
“We are also involved with another inhaled medication approach to treat Covid-19 and have made our knowledge of that treatment available to a partner company in Europe."
What is the partner name?
|
|
|
|
Post by mango on Dec 7, 2020 11:52:30 GMT -5
Some of what we acquired:
QRM-003
QRM-003 is a novel formulation of the known antibiotic clofazimine that is inhaled directly to the lungs via a nebulizer. Clofazimine has shown efficacy against a wide range of NTM isolates including M. avium and M. abscessus. If taken orally, clofazimine tends to accumulate in the liver and spleen first, before the lungs, making clofazimine a prime candidate for inhaled delivery. Qrumpharma is currently conducting acute toxicology studies to enable first in human dosing.
QRM-007
QRM-007 is an inhaled formulation of clofazimine for the treatment of TB. QRM-007 is similar to QRM-003, except that the product is optimized for the low resource settings where TB is more common. QRM-007 will closely follow QRM-003 development to leverage early stage non-clinical and clinical results.
QRM-008
QRM-008 is a novel inhaled formulation of an existing antibiotic that has demonstrated efficacy against both NTM and TB. Prototype formulations have been developed, and in vivo studies in models of NTM and TB pulmonary disease are in preparation. Furthermore, QRM-008 shows synergistic activity with clofazimine, opening the potential for combination products in the future.
|
|
|
|
Post by mnkdfann on Dec 7, 2020 12:00:33 GMT -5
Reprtedly 18 - I would guess 4-6 come over How many employees does Qrum have? Mnkd spent $3M plus $9M in stock plus a bunch of extra salaries. If Matt likes it I guess I'm okay with it too. Where did you find 18? Source/link? A search for QrumPharma on LinkedIn says 1-10, only lists 3, and at least 1 of those is part-time (i.e. given they have a full-time hospital job as well). www.linkedin.com/search/results/all/?keywords=Qrumpharma%20Inc. The QrumPharma LinkedIn page itself, says 0-1 (clearly not up to date, but a far cry from 18). www.linkedin.com/company/aumapharma-llc/Q's Senior Scientist graduated with his PhD fairly recently, in 2017, from The University of Western Ontario (in Canada). Go Mustangs! www.linkedin.com/in/brandon-banaschewski-1a163aaa/As you can see at a link above, QrumPharma still refers to itself as Aumapharma. The Visit Website link at the QrumPharma page still takes you to: www.aumapharma.com |
|
|
|
Post by oldfishtowner on Dec 7, 2020 12:07:54 GMT -5
“ We are currently conducting animal studies of this potential treatment through government and private funding.” Would be curious how much government funding is in play here? “We are also involved with another inhaled medication approach to treat Covid-19 and have made our knowledge of that treatment available to a partner company in Europe." What is the partner name? Since QrumPharma was privately held, there is likely little we can find out about the company's finances, etc.. Maybe Castagna will fill in some of the missing information at his next presentation or at least at the next earnings call, since what was QrumPharma's is now MNKD's. |
|
|
|
Post by nylefty on Dec 7, 2020 12:24:05 GMT -5
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Dec 7, 2020 12:46:50 GMT -5
Revenue may be $3m, but how negative is their net income (profit) I wonder. We don't need any more drags on our bottom line.
... BUT ...
As Oldfishtowner indicated, perhaps Mike's thinking was that this company has some expertise that MNKD needs to assist them in getting started with an inhalable Covid-19 therapy. 2 bangs for 1 buck. Maybe developing their inhalable NTM product can wait for later. If that is it, then I am very happy about this purchase. I would absolutely love to see MNKD develop an inhalable SARS vaccine(s). And if purchasing this company enabled them to jump into Operation Warp Speed AND obtain MNKD's own molecule (and maybe even many more) for future development, then I am ecstatic for MNKD.
|
|
|
|
Post by mnkdfann on Dec 7, 2020 12:54:59 GMT -5
In my experience, Zoominfo isn't a great source for accurate information on small companies. I have a friend who owns a small (20-year old) company, and zoominfo is off by a factor of 10 in its reporting of how many employees it has. IMO, I can't help but think if Qrumpharma had anything close to 18 (especially full-time) employees, more than 3 would be listed as such on LinkedIn. |
|
|
|
Post by harryx1 on Dec 7, 2020 13:06:18 GMT -5
I LIKE IT! Aside from Afrezza (which we know is the most advanced mealtime insulin developed), I've always thought that the Technosphere platform was very well suited to Cystic Fibrosis treatments and could have a huge impact in that disease (greater than Afrezza for diabetes). I truly believe that there could be a huge CF treatment division within Mannkind using Technosphere to create novel treatments as well as using existing molecules to increase the quality of life for CF patients. Acquiring Dr. Hofmann is what is needed to bring CF expertise to Mannkind. This, IMO, will help advance not only the new Clofazimine molecule but also the Tobramycin and Dornase Alfa Technosphere molecules as he has prior relationships with the CF Foundation network through QRM-003. My hope is that other molecules (Amphotericin B and possible delivery of the CFTR-encoded mRNA molecule) will be added to the pipeline in the near future. www.nacfconference.org/Home/PDFs/NACFC_2018_Plenary_1/ |
|
|
|
Post by mango on Dec 7, 2020 13:29:31 GMT -5
|
|
|
|
Post by harryx1 on Dec 7, 2020 13:35:51 GMT -5
Another possibility, but I'm not sure if it can be done (I think I asked Mike a while back but didn't get an answer) is to have a triple therapy by either absorbing 3 molecules onto a Technosphere particle or mixing particles together. This would be a combination of molecules that have an synergistic effect. For example, Moxifloxacin, Ceftazidime, Colistin, or a combination using Tobramycin.
|
|
|
|
Post by buyitonsale on Dec 7, 2020 13:56:47 GMT -5
Another positive business plan development and definitely 1 more catalyst to look forward to by the end of 2021.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 7, 2020 14:53:44 GMT -5
I LIKE IT! Aside from Afrezza (which we know is the most advanced mealtime insulin developed), I've always thought that the Technosphere platform was very well suited to Cystic Fibrosis treatments and could have a huge impact in that disease (greater than Afrezza for diabetes). I truly believe that there could be a huge CF treatment division within Mannkind using Technosphere to create novel treatments as well as using existing molecules to increase the quality of life for CF patients. Acquiring Dr. Hofmann is what is needed to bring CF expertise to Mannkind. This, IMO, will help advance not only the new Clofazimine molecule but also the Tobramycin and Dornase Alfa Technosphere molecules as he has prior relationships with the CF Foundation network through QRM-003. My hope is that other molecules (Amphotericin B and possible delivery of the CFTR-encoded mRNA molecule) will be added to the pipeline in the near future. www.nacfconference.org/Home/PDFs/NACFC_2018_Plenary_1/The question is......Are these molecules going to be a Full product of MNKD or another ROYALTY stream? |
|
|
|
Post by matt on Dec 7, 2020 15:08:49 GMT -5
Revenue may be $3m, but how negative is their net income (profit) I wonder. We don't need any more drags on our bottom line. When a start-up has $3 million in revenue then you can be pretty sure that it is all grant funding, and will be more than offset by a larger investment in R&D. As to how much the cash burn is, that really depends on what is involved in researching these particular drugs. A net operating loss of $5-8 million would not be shocking for a company with 18 employees, and perhaps considerably more. Honestly, if the cash burn is much less than that then it means that there is still a lot of validation work yet to be done on these drugs and this pipeline will take a lot of time to mature. |
|
